27.3.2026 08:00:00 CET | Thor Medical ASA | Annual financial and audit reports

Thor Medical ASA has today published its integrated annual report, including the
sustainability statement, for the financial year ended 31 December 2025, as well
as the remuneration report for 2025.

In his letter to the shareholders and stakeholders of the company, CEO of Thor
Medical, Jasper C. Kurth, writes:

"The momentum behind targeted alpha therapies is accelerating, and reliable
access to thorium-228, radium-224 and lead-212 is becoming a limiting factor for
the industry. Over the past year, we demonstrated our ability to meet that need
as we scale production responsibly and efficiently."

"As we look toward 2026, our priorities are clear: continue to execute the
AlphaOne plant safely and on schedule, prepare for commercial deliveries at
scale, and continue to develop a supply chain capable of supporting an expanding
global market. I want to thank our employees, partners, and shareholders for
their trust and commitment during this important year. Together, we are building
the infrastructure that will enable the next generation of cancer therapies."

The reports are attached and are also available on Thor Medical's website: 
www.thormedical.com - http://www.thormedical.com

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

CONTACTS

 * Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988
   05 724, mathias.reierth@thormedical.com 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium, a key component of next-generation targeted cancer
treatment. Its proprietary production process requires no irradiation or use of
nuclear reactors, and provides a reliable, environmentally friendly and
cost-efficient supply of alpha emitters to the radiopharmaceutical industry.

Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by fueling
next-generation cancer therapies with high-purity isotopes.

Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange under the ticker symbol TRMED. For more information, visit 
www.thormedical.com - https://www.thormedical.com. 

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18847406/6927/Download%20announce
ment%20as%20PDF.pdf

Thor Medical Annual Report 2025.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18847406/6924/Thor%20Medical%20An
nual%20Report%202025.pdf

thormedicalasa-2025-12-31-1-en.zip -
https://kommunikasjon.ntb.no/ir-files/17848634/18847406/6925/thormedicalasa-2025
-12-31-1-en.zip

Thor Medical Remuneration Report 2025.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18847406/6926/Thor%20Medical%20Re
muneration%20Report%202025.pdf